# Adoptive Cell Therapy Across Cancer Diagnoses

> **NCT03296137** · PHASE1,PHASE2 · COMPLETED · sponsor: **Inge Marie Svane** · enrollment: 25 (actual)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** Autologous tumor-infiltrating lymphocytes
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** proleukin
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludara

## Key facts

- **NCT ID:** NCT03296137
- **Lead sponsor:** Inge Marie Svane
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-13
- **Primary completion:** 2020-03-13
- **Final completion:** 2020-07-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03296137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03296137, "Adoptive Cell Therapy Across Cancer Diagnoses". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03296137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*